Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Sees Significant Increase in Short Interest

Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 47,500 shares, an increase of 239.3% from the October 31st total of 14,000 shares. Based on an average daily volume of 40,700 shares, the days-to-cover ratio is currently 1.2 days. Approximately 1.4% of the shares of the company are sold short.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LSB. FMR LLC acquired a new position in shares of Lakeshore Biopharma during the third quarter worth approximately $803,000. Hhlr Advisors LTD. acquired a new stake in shares of Lakeshore Biopharma in the third quarter worth $513,000. Finally, Barclays PLC bought a new position in Lakeshore Biopharma during the third quarter worth $169,000. 52.64% of the stock is currently owned by institutional investors and hedge funds.

Lakeshore Biopharma Trading Down 8.8 %

LSB stock traded down $0.29 during midday trading on Wednesday, hitting $2.98. 14,596 shares of the company traded hands, compared to its average volume of 20,395. Lakeshore Biopharma has a twelve month low of $1.88 and a twelve month high of $11.20. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 0.17. The firm’s 50 day simple moving average is $3.95.

About Lakeshore Biopharma

LakeShore Biopharma Co, Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.